An interventional study of General education control and Decision support tool in Eosinophilic Esophagitis, sponsored by University of Michigan. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by University of Michigan · Not applicable, Interventional, and Health services research
Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 41 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.
Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 45th largest by enrollment of the 111 interventional ones that give a count, is one of 8 that started in 2025, is one of 33 with no phase, reaches primary completion later than 13 of the 40 other live ones, and was the 154th registered.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
Browse Eosinophilic Esophagitis studies →23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Mali
Ages 18–65
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–65
Johns Hopkins University · Sites in United States
Ages 5–21
Kate Farms Inc · Sites in United States
Ages 1–21
Medical College of Wisconsin · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 38 · Phase 3 26 · Phase 4 10
First in 1996; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is above the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.
Median enrollment 36 across the 111 interventional studies, 80 across the 53 observational. Of the 112 that completed or were terminated, 55 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 165 have an industry lead sponsor. The 10 most frequent:
University of Michigan is the lead sponsor of 1,507 studies on the registry; 193 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 133 (79%) have results posted.
University of Michigan has 2 studies filed under Eosinophilic Esophagitis — fewer than ten, so there is no comparison to draw.
10 of the studies in Eosinophilic Esophagitis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596252Phase 3Dr. Falk Pharma GmbHOnce Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | 2026-12 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT03312686Indiana UniversityChanges in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study | 2026-12-31 |
| NCT02008903University of Colorado, DenverEsophageal String Test in Eosinophilic Esophagitis | 2027-01 |
| NCT06598462Uniquity One (UNI)A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 165 studies in Eosinophilic Esophagitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study team is conducting this project to learn more about how patients with eosinophilic esophagitis (EoE) like to use and receive educational materials about treatment options and treatment decision making.
This study will assess the efficacy of a decision support intervention to make decisions about treatment and disease management for patients with EoE and will assess the feasibility and acceptability of the intervention to inform future R01-level studies.
The study team hypothesize that deploying the intervention will be feasible, and it will demonstrate high acceptability among EoE patients. Additionally, that patients that use the intervention (vs general education about EoE) will report greater treatment knowledge, increased readiness to choose a therapy, adherence to therapy, and follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
General educational materials
Behavioral: General education control
Tailored educational materials
Behavioral: Decision support tool
Participants will complete an online survey before reviewing education material for eosinophilic esophagitis, prior to patient's clinical physician's appointment (this appointment is a standard of care visit). Participants will complete a follow-up survey approximately 3 months after the clinic appointment.
Participants will complete an online survey before reviewing tailored educational materials for eosinophilic esophagitis prior to patient's clinical physician's appointment (this appointment is a standard of care visit). The intervention is a tailored, electronic decision support intervention with a patient-facing decision aid (DA) with three components-EoE knowledge/education, values clarifications, and communication. Tailored feedback from the patient will be given to the patient's provider prior to the visit to facilitate shared decision-making in the visit. Participants will complete a follow-up survey approximately 3 months after the clinic appointment.
Feasibility: measured as the proportion of eligible patients that consent to participate in the study
The study aims to achieve at least 20% consented for eligible patients.
Time frame: Recruitment period approximately 18 months
Acceptability: measured on a 4-point Likert scale
Measured on a 4-point Likert-scale (1) Very Unhelpful to (4) Very Helpful. Analyzed as high scores indicate more helpful.
Time frame: Approximately 4 months
Effectiveness (within-subjects)
Objective eosinophilic esophagitis knowledge measured on 8 true/false/I don't know questions where wrong or "I don't know" answers are given 0 points and correct answers are given 1 point. Minimum points=0 and Maximum points=8
Time frame: Day 1 up to approximately 1 month (after consent prior to standard of care clinic visit)
Effectiveness (between-subjects)
Objective eosinophilic esophagitis knowledge measured on 8 true/false/I don't know questions where wrong or "I don't know" answers are given 0 points and correct answers are given 1 point. Minimum points=0 and Maximum points=8
Time frame: Approximately 4 months
Preparation for Decision Making (PrepDM) scale
Preparation for Decision making (PrepDM scale) score is a 10-item questionnaire and is scored on a 0-100 scale, where higher scores indicate participants being well prepared to make decisions after reviewing a decision aid (DA). The Prep-DM scale may be adapted slightly to meet the needs of the target population and the developed decision support tool.
Time frame: Approximately 4 months
Completion rates
Measured as the proportion of people that consented and completed all study measures, the pre-test, post-test, and 3-month follow-up survey
Time frame: Approximately 4 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2025 to primary completion in Sep 2026, 17 months.
Of 23 interventional studies with no phase under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 41. This study's 17 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Oct 2026 → Sep 2026 and completion Dec 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.